MA30782B1 - Amides substitues, procede de production et d'utilisation desdits amides - Google Patents

Amides substitues, procede de production et d'utilisation desdits amides

Info

Publication number
MA30782B1
MA30782B1 MA31766A MA31766A MA30782B1 MA 30782 B1 MA30782 B1 MA 30782B1 MA 31766 A MA31766 A MA 31766A MA 31766 A MA31766 A MA 31766A MA 30782 B1 MA30782 B1 MA 30782B1
Authority
MA
Morocco
Prior art keywords
amides
methods
chemical entity
activity
production
Prior art date
Application number
MA31766A
Other languages
English (en)
Inventor
Peter A Blomgren
Kevin S Currie
Jeffrey E Kropf
Seung H Lee
James W Darrow
Scott A Mitchell
Jianjun Xu
Aaron C Schmitt
Original Assignee
Cgi Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cgi Pharmaceuticals Inc filed Critical Cgi Pharmaceuticals Inc
Publication of MA30782B1 publication Critical patent/MA30782B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE AU MOINS UNE ENTITÉ CHIMIQUE CHOISIE PARMI DES COMPOSÉS DE FORMULE (1) ET DES SELS, DES SOLVATES, DES CHÉLATES, DES COMPLEXES NON-COVALENTS, DES PRO-MÉDICAMENTS DE QUALITÉ PHARMACEUTIQUE, ET DES MÉLANGES DE CES SUBSTANCES. ELLE CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES COMPORTANT AU MOINS UNE ENTITÉ CHIMIQUE SELON L'INVENTION, AINSI QU'UN VÉHICULE DE QUALITÉ PHARMACEUTIQUE CHOISI PARMI DES ADJUVANTS TRANSPORTEURS ET DES EXCIPIENTS. DES MÉTHODES DE TRAITEMENT DE PATIENTS SOUFFRANT DE CERTAINES MALADIES RÉPONDANT À L'INHIBITION DE L'ACTIVITÉ BTK ET / OU DE L'ACTIVITÉ DES LYMPHOCYTES B, AINSI QUE DES MÉTHODES DE DÉTERMINATION DE LA PRÉSENCE DE BTK DANS UN ÉCHANTILLON SONT ÉGALEMENT DÉCRITES.
MA31766A 2006-09-11 2009-04-06 Amides substitues, procede de production et d'utilisation desdits amides MA30782B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84395906P 2006-09-11 2006-09-11

Publications (1)

Publication Number Publication Date
MA30782B1 true MA30782B1 (fr) 2009-10-01

Family

ID=38951317

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31766A MA30782B1 (fr) 2006-09-11 2009-04-06 Amides substitues, procede de production et d'utilisation desdits amides

Country Status (23)

Country Link
US (1) US8058446B2 (fr)
EP (1) EP2081923B1 (fr)
JP (1) JP5295961B2 (fr)
KR (1) KR101442585B1 (fr)
CN (1) CN101679361A (fr)
AR (1) AR063706A1 (fr)
AU (1) AU2007296559B2 (fr)
BR (1) BRPI0716918A2 (fr)
CA (2) CA2661654C (fr)
CL (1) CL2007002640A1 (fr)
CO (1) CO6160313A2 (fr)
CR (1) CR10710A (fr)
EC (1) ECSP099239A (fr)
ES (1) ES2576478T3 (fr)
IL (1) IL197230A0 (fr)
MA (1) MA30782B1 (fr)
MX (1) MX2009002649A (fr)
NO (1) NO20091424L (fr)
PE (1) PE20080839A1 (fr)
RU (1) RU2009113693A (fr)
TW (1) TW200829579A (fr)
WO (1) WO2008033854A1 (fr)
ZA (1) ZA200901633B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838523B2 (en) * 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CN101835755B (zh) 2007-10-23 2013-12-11 霍夫曼-拉罗奇有限公司 激酶抑制剂
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
PH12012502374A1 (en) 2008-06-24 2014-11-12 Hoffmann La Roche Novel substituted pyridin-2-ones and pyridazin-3-ones
PE20110164A1 (es) * 2008-07-02 2011-03-28 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de quinasa
US8598174B2 (en) 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2566869B1 (fr) 2010-05-07 2016-03-02 Gilead Connecticut, Inc. Composés de pyridone et d'aza-pyridone et leurs procédés d'utilisation
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
MX2014005285A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos biciclicos de piperazina.
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2773639B1 (fr) * 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Piperazines alkyles comme inhibiteurs de l'activite btk
MX2014005282A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de 8-fluoroftalazin-1 (2h) -ona.
AU2012382373A1 (en) * 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
SG11201500499TA (en) 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2902686C (fr) 2013-04-25 2017-01-24 Beigene, Ltd. Composes heterocycliques fusionnes en tant qu'inhibiteurs de proteine kinase
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
WO2015000949A1 (fr) 2013-07-03 2015-01-08 F. Hoffmann-La Roche Ag Composés hétéroaryl pyridone et aza-pyridone amide
PE20160605A1 (es) 2013-07-30 2016-07-20 Gilead Connecticut Inc Formulaciones de inhibidores de la syk
KR101810798B1 (ko) 2013-07-30 2017-12-19 질레드 코네티컷 인코포레이티드 Ｓｙｋ 억제제의 다형체
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
SG10201804471PA (en) * 2013-10-18 2018-07-30 Celgene Quanticel Research Inc Bromodomain inhibitors
WO2015082583A1 (fr) 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Composés de pyridone hétéroarylique et d'aza-pyridone à fonctionnalité électrophile
EP3089970B1 (fr) * 2013-12-09 2018-10-17 AbbVie Inc. Dérivés de dihydropyridinone et de dihydropyridazinone utiles comme inhibiteurs de bromodomaines
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
US11319318B2 (en) * 2015-03-05 2022-05-03 Boehringer Ingelheim International Gmbh Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9
WO2017070089A1 (fr) 2015-10-19 2017-04-27 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
MA44075A (fr) * 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017148837A1 (fr) 2016-02-29 2017-09-08 F. Hoffmann-La Roche Ag Compositions de formes galéniques comprenant un inhibiteur de la tyrosine kinase de bruton
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (fr) 2016-05-26 2017-11-30 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
EP3484866B1 (fr) 2016-07-14 2022-09-07 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
WO2018033853A2 (fr) 2016-08-16 2018-02-22 Beigene, Ltd. Forme cristalline de (s)-7-(1-acryloylpipéridin-4-yl)-2-(4-phénoxyphényle)-4,5,6,7-tétra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, sa préparation et ses utilisations
WO2018033135A1 (fr) 2016-08-19 2018-02-22 Beigene, Ltd. Utilisation d'une combinaison comprenant un inhibiteur de btk pour le traitement de cancers
WO2018044783A1 (fr) 2016-08-29 2018-03-08 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
IL292938A (en) 2016-09-19 2022-07-01 Mei Pharma Inc Combined treatment
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
WO2018119221A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
LT3558990T (lt) 2016-12-22 2022-12-27 Incyte Corporation Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CN110709702A (zh) 2017-03-24 2020-01-17 豪夫迈·罗氏有限公司 治疗自身免疫性疾病和炎性疾病的方法
EP3645569A4 (fr) 2017-06-26 2021-03-24 BeiGene, Ltd. Immunothérapie pour carcinome hépatocellulaire
US11377449B2 (en) 2017-08-12 2022-07-05 Beigene, Ltd. BTK inhibitors with improved dual selectivity
EP3672974A1 (fr) 2017-08-25 2020-07-01 Gilead Sciences, Inc. Polymorphes inhibiteurs de syk
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
WO2019108795A1 (fr) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Traitement de lymphomes à cellules b indolentes ou agressives au moyen d'une combinaison comprenant des inhibiteurs de btk
EP3492454A1 (fr) * 2017-11-30 2019-06-05 Step Pharma S.A.S. Composés
EP3717465B1 (fr) 2017-11-30 2026-01-21 Step Pharma S.A.S. Composés
WO2019106156A1 (fr) 2017-11-30 2019-06-06 Step Pharma S.A.S. Composés
SMT202500157T1 (it) 2018-03-30 2025-05-12 Incyte Corp Composti eterociclici come immunomodulatori
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
BR112021005986A2 (pt) 2018-10-23 2021-06-29 Step Pharma S.A.S. derivados de aminopirimidina como inibidores de ctps1
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
US20220249491A1 (en) 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
CA3160131A1 (fr) 2019-11-11 2021-05-20 Incyte Corporation Formes salines et cristallines d'un inhibiteur de pd-1/pd-l1
CR20230230A (es) 2020-11-06 2023-07-27 Incyte Corp Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Procédé de préparation d'un inhibiteur de pd-1/pd-l1
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) * 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
CA2359680A1 (fr) * 1999-01-22 2000-07-27 David M. Armistead Inhibiteurs de kinase
US7405295B2 (en) * 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
AU2005304473A1 (en) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
US8101770B2 (en) 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
MX2007011041A (es) * 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
EP1919906B1 (fr) * 2005-08-29 2011-10-12 Vertex Pharmaceuticals Incorporated Pyrid-2-ones disubstituees en 3, 5 inhibitrices de la famille tec des tyrosine kinases non receptrices
PE20081370A1 (es) * 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
WO2008033858A2 (fr) * 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Inhibiteurs de kinase et procédés d'utilisation et d'identification des inhibiteurs de kinase
US7838523B2 (en) * 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras

Also Published As

Publication number Publication date
ZA200901633B (en) 2009-12-30
IL197230A0 (en) 2009-12-24
MX2009002649A (es) 2009-03-26
US8058446B2 (en) 2011-11-15
CL2007002640A1 (es) 2008-06-20
CN101679361A (zh) 2010-03-24
EP2081923B1 (fr) 2016-03-16
NO20091424L (no) 2009-06-10
EP2081923A1 (fr) 2009-07-29
JP2010504287A (ja) 2010-02-12
US20080139557A1 (en) 2008-06-12
CR10710A (es) 2009-07-14
TW200829579A (en) 2008-07-16
CO6160313A2 (es) 2010-05-20
BRPI0716918A2 (pt) 2013-11-05
RU2009113693A (ru) 2010-10-20
PE20080839A1 (es) 2008-08-23
AR063706A1 (es) 2009-02-11
CA2661654A1 (fr) 2008-03-20
ES2576478T3 (es) 2016-07-07
KR20090074762A (ko) 2009-07-07
CA2661654C (fr) 2016-10-11
AU2007296559A1 (en) 2008-03-20
WO2008033854A1 (fr) 2008-03-20
KR101442585B1 (ko) 2014-10-02
JP5295961B2 (ja) 2013-09-18
ECSP099239A (es) 2009-07-31
CA2941688A1 (fr) 2008-03-20
AU2007296559B2 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
MA30782B1 (fr) Amides substitues, procede de production et d'utilisation desdits amides
MA31276B1 (fr) Amides substitués, procédé de production et d'utilisation desdits amides.
TNSN03130A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
TNSN00121A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
MA30027B1 (fr) [ (1h- indol- 5 -yl) -heteroaryloxy] - (1-aza-bicyclo [3.3.1] nonanes utilises en tant que ligands cholinergiques de n-achr pour le traitement des troubles psychotiques et neurodegeneratifs
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA29387B1 (fr) Inhibiteurs de la dipeptidyl peptidase iv
MA30089B1 (fr) (arylsulfonyl)-pyrasolopiperidines
MA30333B1 (fr) Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete.
MA30047B1 (fr) Procede destine a traiter une lesion articulaire
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MX2007011041A (es) Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
EP1651623A4 (fr) Hexahydrodiazepinones utilises en tant qu'inhibiteurs de la dipeptidyl peptidase iv pour le traitement ou la prevention du diabete
MA30916B1 (fr) Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA28077A1 (fr) Derives d'isoquinilone 1,4-disubstitues en tant qu'inhibiteurs de raf-kinase utiles pour le traitement de maladies proliferantes
MA29810B1 (fr) 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques
MA31894B1 (fr) Composes organiques
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
TN2009000138A1 (fr) Biaryl-ether-urees
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer